Tevogen Bio Holdings Inc. (G28.F)
| Previous close | 0.8800 |
| Open | 0.8900 |
| Bid | 0.8600 x N/A |
| Ask | 0.9500 x N/A |
| Day's range | 0.8900 - 0.8900 |
| 52-week range | 0.8550 - 8.6510 |
| Volume | |
| Avg. volume | 231 |
| Market cap | 156.086M |
| Beta (5Y monthly) | 0.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireTevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
Acquire cell therapy manufacturing facility with clinical and commercial capabilitiesFurther ExacTcell platform for additional clinical trials based on successful completion of POCHighlight full year financial results and clarify key financial items WARREN, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in onc
- GlobeNewswire
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
Conversion of promissory notes into common stock removed $94.9 million in pro forma balance sheet liabilities.The converted common stock is included in the company’s total 165 million outstanding shares.The Tevogen.ai initiative aims to harness the immense potential of AI to enhance drug discovery, development, manufacturing, distribution, and patient access. WARREN, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN) is a clinical-stage
- GlobeNewswire
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
Successful completion of TVGN 489’s proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities.Tevogen Bio plans to continue using its ExacTcellTM technology platform to develop additional products targeting cancer causing viruses: HPV for cervical cancer and EBV for lymphoma. WARREN, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings (Tevogen) (Nasdaq: TVGN), is a clinical-stage specialty immunotherapy bio
